Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 106

Posts Tagged ‘sciex’

CRISPR Researchers to Benefit from COBO Technologies and SCIEX Partnership

Posted by fidest press agency su domenica, 7 luglio 2019

COBO Technologies, a company specialised in quality control services and products in genome editing, today announces a new partnership with SCIEX, a global leader in life science analytical technologies, to develop PIPPR, a unique protein expression analysis platform. Based in Copenhagen, Denmark, Cobo Technologies specialises in products and services for Quality Control of CRISPR-modified cells and animals. The proprietary CRISPR INDEL Profiling Platform (CIPPTM), which is based on the Indel Detection by Amplicon Analysis (IDAATM) methodology and developed for detailed DNA mutation analysis, was launched in December 2017, followed by PIPPR, which was launched in January 2019. PIPPR was created for extensive protein/proteome expression profiling using SWATH® Acquisition.There is an increasing need to do more complexed quality control of cells modified with CRISPR. PIPPR will make it possible to monitor any changes in the protein expression levels in the modified cell. From this data a researcher can easily confirm the quality of any type of CRISPR application and detect potential off-target issues that need to be addressed.“PIPPR identifies and quantifies proteins of all cells and animals modified with CRISPR and the method doesn’t need any antibodies or labelling of proteins. It’s a fast, sensitive, reproducible and robust solution, but also a cost-effective solution that’ll fit any type of CRISPR application,” says Jens-Ole Bock, CEO and founder of Cobo Technologies. “SCIEX is a world-leading company in mass spectrometry instrumentation and innovative software solutions for proteomics and the pharma industry. Combined with COBO Technologies’ expertise of products and services for quality control of CRISPR applications, you have a very powerful collaboration that’ll benefit scientists as well as the two companies.” COBO Technologies and SCIEX will promote the PIPPR platform in conjunction with SWATH Acquisition, the TripleTOF® 6600 LC-MS/MS System and related software solutions from SCIEX. COBO Technologies supports customers globally in both research and clinical fields.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

SCIEX Sponsored Award Recognizes Current and Breakthrough Research in the Field of Electro-Driven Separations

Posted by fidest press agency su venerdì, 9 febbraio 2018

SCIEX, a global leader in life science analytical technologies, has announced that the MSB Strategic Planning Committee has selected Dr. Amy E. Herr, Lester John & Lynne Dewar Lloyd Distinguished Professor of Bioengineering at the University of California, Berkeley, and a Chan Zuckerberg (CZ) Biohub Investigator as the recipient of the 2018 SCIEX Microscale Separations, Innovations Medal and Award, for Current and Breakthrough Research in the Field of Electro-Driven Separations. The Medal Ceremony will be presented on Monday, February 19 as part of a Special Award Plenary Session at the 34th International Symposium on Microscale Bioseparations (MSB 2018) in Rio de Janeiro, RJ, Brazil.
MedalDr. Amy E. Herr, Lester John & Lynne Dewar Lloyd Distinguished Professor of Bioengineering at the University of California, Berkeley, and a Chan Zuckerberg (CZ) Biohub Investigator has been chosen as the recipient of the 2018 SCIEX Microscale Separations, Innovations Medal and Award, for Current and Breakthrough Research in the Field of Electro-Driven Separations. (Photo: Business Wire)The SCIEX Microscale Separations, Innovations Medal and Award (previously the Arnold O’ Beckman Award) is an annual award given to an individual for remarkable career achievements, with particular consideration being given to the development of new methods, techniques and high-impact applications in the field of electro-driven separations. The award is supported by SCIEX, a key driver in capillary electrophoresis technology after integrating the Beckman Coulter CE team in 2014, and comprises of a Medal, a Diploma and a Monetary Prize. Recipients are chosen by a Microscale Separations and Bio-analysis (MSB) Symposium Series selection committee that ranks the candidates according to the recommendation of peers and defined metrics (iCite from NIH).Dr. Herr has been a driving force in providing tools for improved insight into disease progression in cancer, cardiovascular issues and also neurodegenerative diseases. She earned her BS in Engineering and Applied Science from the California Institute of Technology (Caltech), and a MS in Mechanical Engineering and PhD in Mechanical Engineering from Stanford University in 1997, 1999 and 2002, respectively. Dr. Herr began her career as a staff member in the Biosystems Research Group at Sandia National Laboratories in Livermore, CA. Later, she joined the University of California Berkeley, as an Assistant Professor of Bioengineering and was promoted to Associate Professor with tenure in 2012, and ultimately promoted to Full Professor in 2015.
Dr. Herr has been a driving force in providing tools for improved insight into disease progression in cancer, cardiovascular issues and also neurodegenerative diseases. Professor Herr is an elected Fellow of the National Academy of Inventors and the American Institute of Medical and Biological Engineering (AIMBE). She is also a Board Member of the Chemical & Biological Microsystems Society (CBMS), which oversees the microTAS conferences, a standing member of the NIH Nanotechnology Study Section, and is an Advisory Board Member for the UCSF Rosenman Institute and the journals Analytical Chemistry and ACS Sensors. She has served as a Co-Director of the Cold Spring Harbor Laboratory’s Single Cell Analysis summer course as well as Chair and Vice-chair of the Gordon Research Conference (GRC) on the Physics & Chemistry of Microfluidics. She is faculty advisor to the UC Berkeley chapter of the Society of Women Engineers (SWE) and the Graduate Women in Engineering (GWE). (photo: medal)

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

SCIEX Announces Joint Venture With Zhenjang Dian Diagnostics in China

Posted by fidest press agency su martedì, 14 novembre 2017

Hangzhou, ChinaHangzhou, China SCIEX Diagnostics, the in vitro diagnostics (IVD) division of SCIEX, a global leader in mass spectrometry in the life sciences industry, announced today that it has formed a joint venture (JV) with Zhejiang Dian Diagnostics (Dian), a leader in the research, development and supply of medical diagnostic products and services in China. The parties plan to jointly establish a joint venture in Hangzhou, China to develop, register, manufacture, and commercialize Class I, II and III in vitro diagnostic reagents for the SCIEX Triple Quad™ 4500MD LC-MS/MS system, a solution that was approved by the China Food and Drug Administration (CFDA) earlier this year. Mass spectrometry is known to achieve the high sensitivity, specificity and throughput needed in clinical testing areas such as therapeutic drug measurement, vitamin and steroid hormones, and measurements of inherited metabolic diseases, but the lack of readily available IVD assays has made this technology inaccessible to the majority of hospital labs in China where lab-developed tests (LDT) are limited. By combining SCIEX LC-MS/MS and assay development expertise, with Dian’s laboratory network, cold chain logistics, and China-IVD manufacturing expertise, it is expected that the partnership will accelerate China’s clinical laboratory program and make diagnostic and wellness testing more widespread in the region. As one of the leading diagnostic companies in China, Dian’s diagnostic network stretches to more than 30 laboratories, covering almost all of mainland China, processing more than 100,000 clinical samples per day. To advance clinical diagnostics in China, Dian has also established “precision treatment centers” with high-end “Tier 3” medical institutions, and has a developed a comprehensive service for secondary-level “Tier 2” hospitals and beyond. “Modern-day China contends with many lifestyle factors that can lead to illness. Our aim is to provide wellness testing resources that can help hospitals identify potential health risks before they become chronic,” said Inese Lowenstein, President of SCIEX. “Dian has established many product channels with its wide coverage of high-end medical resources, and this venture will further enrich their existing in vitro diagnostic product lines to enable hospital labs to expand their testing capabilities, and perform tests that they previously were not able to.” “It is an important decision and major breakthrough for Dian to collaborate with SCIEX to promote the industrialization and localization of clinical mass spectrometry,” said Hai bin Chen, Chairman Zhenjang Dian Diagnostics. “This joint venture is the first of its kind in China, and by also working closely with CFDA and Health and Family Planning Commission, we believe it will have a profound influence on the future of wellness and diagnostic testing in China.” A ceremony celebrating the venture will take place at Zhejiang Dian Diagnostics headquarters in Hangzhou, China, on November 11, 2017 attended by SCIEX Senior Leadership Executives.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »